risperidone has been researched along with Parkinson Disease, Secondary in 20 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 9.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 5.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or quetiapine in patients with dementia and examined the effects of dose and sex on the risk of parkinsonism." | 3.78 | Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex. ( Anderson, GM; Fischer, HD; Herrmann, N; Marras, C; Rochon, PA; Wang, X, 2012) |
| " We used the Generalized Propensity Score method to evaluate the dose-response risk of Parkinsonism associated with SGAs." | 1.56 | Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study. ( Chyou, TY; Nishtala, PS; Nishtala, R, 2020) |
| " EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale." | 1.42 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. ( Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015) |
| "Risperidone was associated with higher increases in DyskinesiaS compared with quetiapine (P < 0." | 1.42 | Neurological Adverse Effects of Antipsychotics in Children and Adolescents. ( Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015) |
| "Risperidone (4 mg/day) was added to her drug regimen and after increasing the dosage to 6 mg/day, she began to exhibit retrocollis." | 1.31 | Tardive dystonia provoked by concomitantly administered risperidone. ( Hori, M; Hori, T; Kawanishi, Y; Shiraishi, H; Suzuki, T; Tachikawa, H, 2000) |
| "Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors." | 1.30 | Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. ( Heinz, A; Knable, MB; Raedler, T; Weinberger, DR, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chyou, TY | 1 |
| Nishtala, R | 1 |
| Nishtala, PS | 1 |
| Bolu, A | 1 |
| Garip, B | 1 |
| Öznur, T | 1 |
| Uzun, Ö | 1 |
| Carbon, M | 1 |
| Kapoor, S | 1 |
| Sheridan, E | 1 |
| Al-Jadiri, A | 1 |
| Azzo, S | 1 |
| Sarkaria, T | 1 |
| Kane, JM | 1 |
| Saito, E | 1 |
| Correll, CU | 1 |
| Garcia-Amador, M | 1 |
| Merchán-Naranjo, J | 1 |
| Tapia, C | 1 |
| Moreno, C | 1 |
| Castro-Fornieles, J | 1 |
| Baeza, I | 1 |
| de la Serna, E | 1 |
| Alda, JA | 1 |
| Muñoz, D | 1 |
| Andrés Nestares, P | 1 |
| Cantarero, CM | 1 |
| Arango, C | 1 |
| Lamkin, S | 1 |
| Buhl, D | 1 |
| Karanec, K | 1 |
| McWilliams-Dunnigan, L | 1 |
| Alshekhlee, A | 1 |
| Baez, MA | 1 |
| Avery, J | 1 |
| Marras, C | 1 |
| Herrmann, N | 1 |
| Anderson, GM | 1 |
| Fischer, HD | 1 |
| Wang, X | 1 |
| Rochon, PA | 1 |
| Wöhrle, JC | 1 |
| Weigel, R | 1 |
| Grips, E | 1 |
| Blahak, C | 1 |
| Capelle, HH | 1 |
| Krauss, JK | 1 |
| Mateos, JJ | 1 |
| Lomeña, F | 1 |
| Parellada, E | 1 |
| Mireia, F | 1 |
| Fernandez-Egea, E | 1 |
| Pavia, J | 1 |
| Prats, A | 1 |
| Pons, F | 1 |
| Bernardo, M | 1 |
| Høyberg, OJ | 1 |
| Fensbo, C | 1 |
| Remvig, J | 1 |
| Lingjaerde, O | 1 |
| Sloth-Nielsen, M | 1 |
| Salvesen, I | 1 |
| Rich, SS | 1 |
| Friedman, JH | 1 |
| Ott, BR | 1 |
| Maany, I | 1 |
| Gwinn, KA | 1 |
| Caviness, JN | 1 |
| Knable, MB | 1 |
| Heinz, A | 1 |
| Raedler, T | 1 |
| Weinberger, DR | 1 |
| Breier, AF | 1 |
| Malhotra, AK | 1 |
| Su, TP | 1 |
| Pinals, DA | 1 |
| Elman, I | 1 |
| Adler, CM | 1 |
| Lafargue, RT | 1 |
| Clifton, A | 1 |
| Pickar, D | 1 |
| Roberts, MD | 1 |
| Tachikawa, H | 1 |
| Suzuki, T | 1 |
| Kawanishi, Y | 1 |
| Hori, M | 1 |
| Hori, T | 1 |
| Shiraishi, H | 1 |
| Wirshing, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers[NCT00001320] | 265 participants | Observational | 1991-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for risperidone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
3 trials available for risperidone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Down-Regu | 2007 |
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isox | 1993 |
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; Double-Blind Method | 1999 |
15 other studies available for risperidone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Databases, Factual; Female; Humans; Inci | 2020 |
Case of risperidone-induced tardive parkinsonism.
Topics: Adult; Antipsychotic Agents; Humans; Male; Parkinson Disease, Secondary; Risperidone; Schizophrenia; | 2019 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dru | 2015 |
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Drug-Related Side Effect | 2015 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesi | 2009 |
Retropulsion and back bruises in drug-induced parkinsonism.
Topics: Accidental Falls; Aged; Antipsychotic Agents; Back; Biomechanical Phenomena; Bipolar Disorder; Contu | 2010 |
Improvement in drug-induced parkinsonism with electroconvulsive therapy.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Depressive Disorder, Major; Electroconvulsive Ther | 2011 |
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Dementia; Dibenzothi | 2012 |
Risperidone-responsive segmental dystonia and pallidal deep brain stimulation.
Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Cyclohexanols; Depression; Dopamine Antagoni | 2003 |
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
Topics: Aged; Antiparkinson Agents; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Parkinson Disease; Pa | 1995 |
Adverse interaction of tacrine and haloperidol.
Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson | 1996 |
Risperidone-induced tardive dyskinesia and parkinsonism.
Topics: Aged; Antipsychotic Agents; Bipolar Disorder; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Exa | 1997 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Anta | 1997 |
Risperdal and parkinsonian tremor.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 1999 |
Tardive dystonia provoked by concomitantly administered risperidone.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 2000 |